GeoVax will discontinue its GEO-CM04S1 COVID-19 vaccine to redirect resources toward GEO-MVA, which has released material for a planned Phase 3 immunobridging trial targeting expedited regulatory submission and potential Emergency Use Authorization. The company will launch a Phase 2 neoadjuvant Gedeptin trial with pembrolizumab, pursuing global supply deals for GEO-MVA.
GeoVax has strategically reallocated resources away from its GEO-CM04S1 COVID-19 vaccine program to concentrate on higher-value assets and streamline its development pipeline.
The Modified Vaccinia Ankara–based GEO-MVA program has released clinical material in preparation for a pivotal Phase 3 immunobridging trial intended to support expedited regulatory submission and potential Emergency Use Authorization for orthopoxvirus protection.
GeoVax plans a Phase 2 neoadjuvant study of its Gedeptin gene-directed enzyme prodrug therapy in combination with pembrolizumab and fludarabine to enhance tumor immune visibility and potentially improve checkpoint inhibitor responses in head and neck cancers.
The company has initiated engagement with government agencies and preparedness stakeholders worldwide to secure vaccine supply agreements that bolster orthopoxvirus stockpiling, biodefense preparedness, and supply-chain resilience for GEO-MVA.
